These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 26249845)
21. Factors influencing response to intravenous lacosamide in emergency situations: LACO-IV study. Garcés M; Villanueva V; Mauri JA; Suller A; García C; López González FJ; Rodríguez Osorio X; Fernández Pajarín G; Piera A; Guillamón E; Santafé C; Castillo A; Giner P; Torres N; Escalza I; Del Villar A; García de Casasola MC; Bonet M; Noé E; Olmedilla N Epilepsy Behav; 2014 Jul; 36():144-52. PubMed ID: 24922617 [TBL] [Abstract][Full Text] [Related]
22. Synergism of lacosamide with established antiepileptic drugs in the 6-Hz seizure model in mice. Shandra A; Shandra P; Kaschenko O; Matagne A; Stöhr T Epilepsia; 2013 Jul; 54(7):1167-75. PubMed ID: 23750855 [TBL] [Abstract][Full Text] [Related]
23. The pharmacokinetic inter-relationship of tiagabine in blood, cerebrospinal fluid and brain extracellular fluid (frontal cortex and hippocampus). Wang X; Ratnaraj N; Patsalos PN Seizure; 2004 Dec; 13(8):574-81. PubMed ID: 15519917 [TBL] [Abstract][Full Text] [Related]
24. Effects of adjunctive lacosamide on mood and quality of life in patients with epilepsy. Nakhutina L; Kunnakkat SD; Coleman M; Lushbough C; Arnedo V; Soni N; Grant AC Epilepsy Behav; 2017 Aug; 73():90-94. PubMed ID: 28623755 [TBL] [Abstract][Full Text] [Related]
25. Effect of lacosamide on structural damage and functional recovery after traumatic brain injury in rats. Pitkänen A; Immonen R; Ndode-Ekane X; Gröhn O; Stöhr T; Nissinen J Epilepsy Res; 2014 May; 108(4):653-65. PubMed ID: 24636248 [TBL] [Abstract][Full Text] [Related]
26. Lacosamide in the treatment of patients with epilepsy and intellectual disabilities: A long-term study of 136 patients. Böttcher S; Lutz MT; Mayer T Epilepsia; 2017 Oct; 58(10):1749-1754. PubMed ID: 28804872 [TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics of methotrexate in cerebrospinal fluid and serum after osmotic blood-brain barrier disruption in patients with brain lymphoma. Zylber-Katz E; Gomori JM; Schwartz A; Lossos A; Bokstein F; Siegal T Clin Pharmacol Ther; 2000 Jun; 67(6):631-41. PubMed ID: 10872645 [TBL] [Abstract][Full Text] [Related]
28. Comparison of serum, cerebrospinal fluid and brain extracellular fluid pharmacokinetics of lamotrigine. Walker MC; Tong X; Perry H; Alavijeh MS; Patsalos PN Br J Pharmacol; 2000 May; 130(2):242-8. PubMed ID: 10807660 [TBL] [Abstract][Full Text] [Related]
29. Intravenous lacosamide in seizure emergencies: Observations from a hospitalized in-patient adult population. d'Orsi G; Pascarella MG; Martino T; Carapelle E; Pacillo F; Di Claudio MT; Mancini D; Trivisano M; Avolio C; Specchio LM Seizure; 2016 Nov; 42():20-28. PubMed ID: 27693808 [TBL] [Abstract][Full Text] [Related]
30. Lacosamide use in children with epilepsy: Retention rate and effect of concomitant sodium channel blockers in a large cohort. McGinnis E; Kessler SK Epilepsia; 2016 Sep; 57(9):1416-25. PubMed ID: 27430392 [TBL] [Abstract][Full Text] [Related]
31. [Pharmacokinetics of ACNU in cerebrospinal fluid]. Imagawa K; Kawasaki M; Toda I; Hayashi M; Asai A; Nomura T Gan To Kagaku Ryoho; 1982 Sep; 9(9):1543-8. PubMed ID: 6964049 [TBL] [Abstract][Full Text] [Related]
32. The longer-term cognitive effects of adjunctive antiepileptic treatment with lacosamide in comparison with lamotrigine and topiramate in a naturalistic outpatient setting. Helmstaedter C; Witt JA Epilepsy Behav; 2013 Feb; 26(2):182-7. PubMed ID: 23318473 [TBL] [Abstract][Full Text] [Related]
33. Cognitive effects of lacosamide as adjunctive therapy in refractory epilepsy. IJff DM; van Veenendaal TM; Majoie HJ; de Louw AJ; Jansen JF; Aldenkamp AP Acta Neurol Scand; 2015 Jun; 131(6):347-54. PubMed ID: 25630655 [TBL] [Abstract][Full Text] [Related]
34. Drug concentrations in the serum and cerebrospinal fluid of patients treated with cefoperazone/sulbactam after craniotomy. Wang Q; Wu Y; Chen B; Zhou J BMC Anesthesiol; 2015; 15():33. PubMed ID: 25798070 [TBL] [Abstract][Full Text] [Related]
35. Lacosamide on background eeg activity in brain tumor-related epilepsy patients: A case series study. Maschio M; Zarabla A; Maialetti A; Sperati F; Dinapoli L; Dispenza S; Petreri G; Cantelmi T Brain Behav; 2018 Nov; 8(11):e01067. PubMed ID: 30334378 [TBL] [Abstract][Full Text] [Related]
36. Usefulness of intravenous lacosamide in status epilepticus. Santamarina E; Toledo M; Sueiras M; Raspall M; Ailouti N; Lainez E; Porta I; De Gracia R; Quintana M; Alvarez-Sabín J; Xavier Salas Puig XS J Neurol; 2013 Dec; 260(12):3122-8. PubMed ID: 24122063 [TBL] [Abstract][Full Text] [Related]
37. Potential role for human P-glycoprotein in the transport of lacosamide. Zhang C; Chanteux H; Zuo Z; Kwan P; Baum L Epilepsia; 2013 Jul; 54(7):1154-60. PubMed ID: 23551115 [TBL] [Abstract][Full Text] [Related]
38. A novel action of lacosamide on GABA Ruffolo G; Di Bonaventura C; Cifelli P; Roseti C; Fattouch J; Morano A; Limatola C; Aronica E; Palma E; Giallonardo AT Neurobiol Dis; 2018 Jul; 115():59-68. PubMed ID: 29621596 [TBL] [Abstract][Full Text] [Related]
39. Racial variations in lacosamide serum concentrations in adult patients with epilepsy. Zutshi D; Yarraguntla K; Mahulikar A; Seraji-Bozorgzad N; Shah AK; Basha MM J Neurol Sci; 2020 May; 412():116742. PubMed ID: 32126366 [TBL] [Abstract][Full Text] [Related]
40. Effects of CYP2C19 genetic polymorphisms on the pharmacokinetics of lacosamide in Korean patients with epilepsy. Ahn SJ; Oh J; Kim DY; Son H; Hwang S; Shin HR; Kim EY; Lee HS; Lee WJ; Moon J; Lee ST; Jung KH; Park KI; Jung KY; Lee S; Yu KS; Chu K; Lee SK Epilepsia; 2022 Nov; 63(11):2958-2969. PubMed ID: 36039802 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]